Clinical Trial Search

Primary: Overall Survival — 11.1; 11.3 months — p=0.863

Primary: Restless Legs Syndrome (RLS) Symptom Severity — 22.30; 22.40; 22.10; 22.40 Units on a Scale

Primary: ACR20 Responses at Week 24 — 11; 54 participants

Primary: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. — 0.248; 0.401 Liter — p=<0.0001

Primary: Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set) — -36.0; -35.3 milliliter — p=0.8942

Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (rTNSS) — -5.6; -4.7; -4.2; -2.9 units on a scale

Primary: Final Height — 145.90; 150.06; 153.27; 155.59 cm

Primary: The Percent of Out of Range (OOR) International Normalized Prothrombin Time Ratio (INRs) in the Standard and Modified Pharmacogenetic Arms. — 30.6; 31.8 percent — p=<0.05

Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants

Primary: Pearl Index up to 3 Years — 0.33; 0.31 Pregnancies per 100 women years

Primary: Progression-free Survival — 7.2; 5.1 Months

Primary: Change From Baseline at Week 6 and Week 12 for Wrist Flexor Muscle Tone as Measured on the Modified Ashworth Scale (MAS) — -1.21; -1.33; -0.88; -1.12 scores on a scale…

Primary: Disability Rating Scale: Functional Status — 17.3; 18.7; 17.1; 17.8 units on a scale — p=0.007

Primary: Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005) — 310; 182; 97 days — p=<0.001

Primary: Change From Baseline in the Mean Daily Number of Incontinence Episodes at the End of Treatment — -1.08; -0.99 number of daily episodes — p=0.569